Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication PROTONIX For Delayed-Release Oral Suspension and PROTONIX Delayed-Release Tablets are indicated for: PROTONIX is a proton pump inhibitor (PPI) indicated for the following: • Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) ( 1.1 ) • Maintenance of Healing of Erosive Esophagitis ( 1.2 ) • Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome… FDA label
Also known as Pantoprazole Sodium
Pantoprazole · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Pantoprazole Sodium | EXPERIMENTAL | Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddys Laboratories Limited |
| Protonix | ACTIVE_COMPARATOR | Protonix 40 mg DR Tablets of Wyeth Laboratories |
| Name | Type | Description |
|---|---|---|
| Pantoprazole Sodium | DRUG | Pantoprazole Sodium DR Tablets 40 mg |
Inclusion Criteria: 1. Subjects will provide written informed consent. 2. Subjects must be healthy human beings within 18-45 years of age (inclusive) weighing at least 50 kg. 3. Subjects must be within ±10% of ideal body weight in relation to height according to Life Insurance Corporation of India ...
Pantoprazole is a small molecule drug developed by Dr. Reddy's Laboratories Ltd, which trades under the ticker RDY. It is being studied in Phase 1 clinical trials for metabolic conditions related to fed and fasting states. Pantoprazole is also known as pantoprazole sodium.
Pantoprazole targets ATP4A and ATP4B. It acts as an inhibitor of these targets. This mechanism is relevant to its development as a small molecule therapeutic.
Pantoprazole is developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed under the ticker RDY. The company is responsible for the clinical development of this drug candidate.
Pantoprazole is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 trials have been completed.
Pantoprazole has been studied in two completed Phase 1 trials: NCT01283932, a bioequivalence study under fed conditions with 52 participants, and NCT01283919, a bioequivalence study under fasting conditions with 42 participants. Both trials were conducted in India.
Yes, Pantoprazole is also known as Pantoprazole Sodium. They refer to the same drug substance developed by Dr. Reddy's Laboratories Ltd.